Literature DB >> 24101803

Efficacy of a piglet-specific commercial inactivated vaccine against Porcine circovirus type 2 in clinical field trials.

Kiwon Han1, Hwi Won Seo, Yeonsu Oh, Changhoon Park, Ikjae Kang, Hyun Jang, Chanhee Chae.   

Abstract

The efficacy of a piglet-specific inactivated Porcine circovirus type 2 (PCV2) vaccine was evaluated with clinical field trials, as recommended by the Republic of Korea's Animal, Plant & Fisheries Quarantine & Inspection Agency. Three farms were selected on the basis of their history of postweaning multisystemic wasting syndrome. On each farm 60, 1-week-old pigs were randomly allocated to 1 of 2 treatment groups: vaccination at 1 and 3 wk of age or no vaccination. The 2-dose schedule of vaccination with inactivated PCV2 vaccine improved the average daily weight gain from birth to 16 wk of age, the PCV2 load in the blood, and the frequency and severity of lymph node lesions. Inactivated PCV2 vaccine seems to be very effective in controlling PCV2 infection under field conditions.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24101803      PMCID： PMC3700452     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN： 0830-9000            Impact factor:   1.310


  11 in total

Review 1.  Postweaning multisystemic wasting syndrome: a review of aetiology, diagnosis and pathology.

Authors:  C Chae
Journal:  Vet J       Date:  2004-07       Impact factor: 2.688

2.  Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2.

Authors:  D Kim; C H Kim; K Han; H W Seo; Y Oh; C Park; I Kang; C Chae
Journal:  Vaccine       Date:  2011-02-24       Impact factor: 3.641

Review 3.  A review of porcine circovirus 2-associated syndromes and diseases.

Authors:  C Chae
Journal:  Vet J       Date:  2005-05       Impact factor: 2.688

4.  One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions.

Authors:  Paolo Martelli; Luca Ferrari; Marina Morganti; Elena De Angelis; Paolo Bonilauri; Stefano Guazzetti; Antonio Caleffi; Paolo Borghetti
Journal:  Vet Microbiol       Date:  2010-12-14       Impact factor: 3.293

Review 5.  Commercial porcine circovirus type 2 vaccines: efficacy and clinical application.

Authors:  Chanhee Chae
Journal:  Vet J       Date:  2012-07-28       Impact factor: 2.688

6.  A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circovirus type 2.

Authors:  Kyle P Horlen; Steve S Dritz; Jerome C Nietfeld; Steven C Henry; Richard A Hesse; Richard Oberst; Michael Hays; Joseph Anderson; Raymond R R Rowland
Journal:  J Am Vet Med Assoc       Date:  2008-03-15       Impact factor: 1.936

7.  Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2.

Authors:  T Opriessnig; A R Patterson; J Elsener; X J Meng; P G Halbur
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

8.  The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex.

Authors:  Vicky Fachinger; Ralf Bischoff; Samir Ben Jedidia; Armin Saalmüller; Knut Elbers
Journal:  Vaccine       Date:  2007-12-07       Impact factor: 3.641

9.  Efficacy of different protocols of vaccination against porcine circovirus type 2 (PCV2) in a farm affected by postweaning multisystemic wasting syndrome (PMWS).

Authors:  Zygmunt Pejsak; Katarzyna Podgórska; Marian Truszczyński; Paweł Karbowiak; Tomasz Stadejek
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2009-11-12       Impact factor: 2.268

10.  A genetically engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves clinical, pathological and virological outcomes in postweaning multisystemic wasting syndrome affected farms.

Authors:  J Segalés; A Urniza; A Alegre; T Bru; E Crisci; M Nofrarías; S López-Soria; M Balasch; M Sibila; Z Xu; H-J Chu; L Fraile; J Plana-Duran
Journal:  Vaccine       Date:  2009-10-01       Impact factor: 3.641
View more
  1 in total

1.  Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d.

Authors:  Oleksandr Kolyvushko; Agm Rakibuzzaman; Angela Pillatzki; Brett Webb; Sheela Ramamoorthy
Journal:  Vet Sci       Date:  2019-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.